MDXG (MiMedx Group) Valuation Rank


MDXG MiMedx Group Inc MDXG
57 GF Score
Price $3.93
GF Value $6.96
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is MiMedx Group Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

MiMedx Group Valuation Rank Related Terms

MDXG
57GF Score
MiMedx Group Inc MDXG
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is MiMedx Group (MDXG) Overvalued in 2026?

Based on GuruFocus' analysis, MiMedx Group stock appears to be undervalued. The current stock price of $3.93 is trading 43.5% below its estimated GF Value™ of $6.96. GuruFocus considers MiMedx Group to be Significantly Undervalued.

Key valuation signals for MDXG:

  • Valuation Rank:
  • GF Value™: $6.96 vs. price of $3.93 (43.5% below fair value)
  • GF Score™: 57/100 with 2 warning signs

No single metric tells the full story. See the MDXG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

MiMedx Group Business Description

Address 1775 West Oak Commons Court, NE, Marietta, GA, USA, 30062
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, the company sells allografts for ophthalmic surgery and dental applications through licenses to third parties.
57GF Score

Get the complete analysis for MDXG

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.93
Price
$6.96
GF Value